Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Aug 22;7(1):9094.
doi: 10.1038/s41598-017-09097-1.

Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study

Affiliations
Meta-Analysis

Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study

Yang Hu et al. Sci Rep. .

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with poorly understood etiology. Increasing evidence suggest that inflammation may play a critical role in the pathogenesis of ALS. Several studies have demonstrated altered levels of blood cytokines in ALS, but results were inconsistent. Therefore, we did a systematic review of studies comparing blood inflammatory cytokines between ALS patients and control subjects, and quantitatively combined the clinical data with a meta-analysis. The systematic review of Pubmed and Web of Science identified 25 studies encompassing 812 ALS patients and 639 control subjects. Random-effects meta-analysis demonstrated that blood tumor necrosis factor-α (TNF; Hedges' g = 0.655; p = 0.001), TNF receptor 1 (Hedges' g = 0.741; p < 0.001), interleukin 6 (IL-6; Hedges' g = 0.25; p = 0.005), IL-1β (Hedges' g = 0.296; p = 0.038), IL-8 (Hedges' g = 0.449; p < 0.001) and vascular endothelial growth factor (Hedges' g = 0.891; p = 0.003) levels were significantly elevated in patients with ALS compared with control subjects. These results substantially enhance our knowledge of the inflammatory response in ALS, and peripheral blood inflammatory cytokines may be used as diagnostic biomarkers for ALS in the future.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
PRISMA flowchart of the literature search.
Figure 2
Figure 2
Studies of peripheral blood TNF-α and TNFR1. Forest plot displaying random effects meta-analysis results of the association between TNF- α (A), TNFR1 (B) and ALS. The sizes of the squares are proportional to study weights.
Figure 3
Figure 3
Studies of peripheral blood IL-1β and IL-6. Forest plot displaying random effects meta-analysis results of the association between IL-1β (A), IL-6 (B) and ALS. The sizes of the squares are proportional to study weights.
Figure 4
Figure 4
Studies of peripheral blood IL-8 and VEGF. Forest plot displaying random effects meta-analysis results of the association between IL-8 (A), VEGF (B) and ALS. The sizes of the squares are proportional to study weights.

References

    1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. The New England journal of medicine. 2001;344:1688–1700. doi: 10.1056/NEJM200105313442207. - DOI - PubMed
    1. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Annals of neurology. 2009;65(Suppl 1):S3–9. doi: 10.1002/ana.21543. - DOI - PubMed
    1. Mehta P, et al. Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011. MMWR supplements. 2014;63:1–14. - PubMed
    1. Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942–955. doi: 10.1016/S0140-6736(10)61156-7. - DOI - PubMed
    1. Miller, R. G., Mitchell, J. D. & Moore, D. H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). The Cochrane database of systematic reviews, CD001447, doi:10.1002/14651858.CD001447.pub3 (2012).

Publication types